Loading...
Header Logo
Keywords
Last Name
Institution

JAMES C YAO

TitleProfessor
InstitutionMD Anderson
DepartmentGI Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Shen C, Gu D, Zhou S, Xu Y, Sarshekeh AM, Halperin D, Shih YT, Yao JC, Dasari A. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas. 2019 Nov/Dec; 48(10):1373-1379. PMID: 31688604.
      View in: PubMed
    2. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 Oct 15; 25(20):6107-6118. PMID: 31363003.
      View in: PubMed
    3. Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877. PMID: 31254410.
      View in: PubMed
    4. Romero Arenas MA, Olsen C, Yao JC. Recurrence of Metastatic Pro-insulinoma Nearly 50 Years After Subtotal Pancreatectomy. J Gastrointest Cancer. 2019 Jun; 50(2):345-348. PMID: 29110229.
      View in: PubMed
    5. Samdani RT, Wasylishen AR, Halperin DM, Dasari A, Yao JC, Rashid A, Estrella JS. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas. 2019 04; 48(4):510-513. PMID: 30946241.
      View in: PubMed
    6. Parseghian CM, Tam AL, Yao J, Ensor J, Ellis LM, Raghav K, Overman MJ. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol. 2019 03 01; 5(3):402-405. PMID: 30383128.
      View in: PubMed
    7. Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas. 2019 03; 48(3):381-386. PMID: 30768575.
      View in: PubMed
    8. Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. Onco Targets Ther. 2019; 12:1717-1728. PMID: 30881026.
      View in: PubMed
    9. Yao JC, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, Van Cutsem E, Singh S, Fazio N, He W, Riester M, Patel P, Voi M, Morrissey M, Pavel ME, Kulke MH. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. Endocr Relat Cancer. 2019 04 01; 26(4):391-403. PMID: 30667365.
      View in: PubMed
    10. Serpas VJ, Raghav KP, Halperin DM, Yao J, Overman MJ. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol. 2018 12 12; 18(1):169. PMID: 30541475.
      View in: PubMed
    11. Balanescu DV, Donisan T, Lopez-Mattei J, Hassan S, Kim P, Dasari A, Halperin D, Yao J, Kar B, Gregoric I, Balanescu SM, Iliescu C. The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment. Oncol Lett. 2019 May; 17(5):4126-4132. PMID: 30944605.
      View in: PubMed
    12. Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics. 2018 08; 36(8):1005-1013. PMID: 29682693.
      View in: PubMed
    13. Ng CS, Wei W, Duran C, Ghosh P, Anderson EF, Chandler AG, Yao JC. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents. Abdom Radiol (NY). 2018 07; 43(7):1661-1669. PMID: 29075824.
      View in: PubMed
    14. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 06; 16(6):693-702. PMID: 29891520.
      View in: PubMed
    15. Cloyd JM, Omichi K, Mizuno T, Kawaguchi Y, Tzeng CD, Conrad C, Chun YS, Aloia TA, Katz MHG, Lee JE, Halperin D, Yao J, Vauthey JN, Dasari A. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol. 2018 Jun; 25(6):1709-1715. PMID: 29626307.
      View in: PubMed
    16. Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. Oncologist. 2018 07; 23(7):766-e90. PMID: 29242283.
      View in: PubMed
    17. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 2018 02 15; 124(4):807-815. PMID: 29211313.
      View in: PubMed
    18. Voong KR, Rashid A, Crane CH, Minsky BD, Krishnan S, Yao JC, Wolff RA, Skibber JM, Feig BW, Chang GJ, Das P. Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal. Am J Clin Oncol. 2017 Dec; 40(6):555-560. PMID: 26237193.
      View in: PubMed
    19. Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Bubuteishvili-Pacaud L, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan; 109(1):174-181. PMID: 29055056.
      View in: PubMed
    20. Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther. 2017; 10:5013-5030. PMID: 29081664.
      View in: PubMed
    21. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 01; 3(10):1335-1342. PMID: 28448665.
      View in: PubMed
    22. Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 10; 18(10):1411-1422. PMID: 28838862.
      View in: PubMed
    23. Mehrvarz Sarshekeh A, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, Dasari A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget. 2017 11 21; 8(59):99541-99551. PMID: 29245922.
      View in: PubMed
    24. Parseghian CM, Raghav K, Wolff RA, Ensor J, Yao J, Ellis LM, Tam AL, Overman MJ. Underreporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res. 2017 Nov 01; 23(21):6450-6457. PMID: 28754815.
      View in: PubMed
    25. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242. PMID: 28683459.
      View in: PubMed
    26. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 07; 46(6):707-714. PMID: 28609356.
      View in: PubMed
    27. Pavel ME, Chen D, He W, Cushman S, Voi M, de Vries EGE, Baudin E, Yao JC. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. Pancreas. 2017 07; 46(6):751-757. PMID: 28609362.
      View in: PubMed
    28. Yao JC, Chan JA, Mita AC, Kundu MG, Hermosillo Reséndiz K, Hu K, Ravichandran S, Strosberg JR, Wolin EM. Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors. Onco Targets Ther. 2017; 10:3177-3186. PMID: 28721067.
      View in: PubMed
    29. Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462. PMID: 28642335.
      View in: PubMed
    30. Halperin DM, Shen C, Yao JC. Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply. Lancet Oncol. 2017 06; 18(6):e300. PMID: 28593855.
      View in: PubMed
    31. Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, Lahner H, Valle JW, Voi M, Bubuteishvili-Pacaud L, Lincy J, Wolin E, Okita N, Libutti SK, Oh DY, Kulke M, Strosberg J, Yao JC, Pavel ME, Fazio N. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2018; 106(3):211-220. PMID: 28554173.
      View in: PubMed
    32. Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Meric-Bernstam F, Fu S. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806. PMID: 28430579.
      View in: PubMed
    33. Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017 May 20; 35(15):1695-1703. PMID: 28384065.
      View in: PubMed
    34. Qiu W, Christakis I, Stewart AA, Vodopivec DM, Silva-Figueroa A, Chen H, Woodard TL, Halperin DM, Lee JE, Yao JC, Perrier ND. Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1? Clin Endocrinol (Oxf). 2017 Jun; 86(6):791-797. PMID: 28273369.
      View in: PubMed
    35. Tang C, Sherman SI, Price M, Weng J, Davis SE, Hong DS, Yao JC, Buzdar A, Wilding G, Lee JJ. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421. PMID: 28275168.
      View in: PubMed
    36. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 04; 18(4):525-534. PMID: 28238592.
      View in: PubMed
    37. Yao JC, Voi M, Lincy J, Pavel M. Reply to V. Amoroso et al. J Clin Oncol. 2017 05 01; 35(13):1488-1489. PMID: 28113028.
      View in: PubMed
    38. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135. PMID: 28076709.
      View in: PubMed
    39. Halperin DM, Yao JC, Dasari A. What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2017 01 20; 35(3):265-267. PMID: 27893328.
      View in: PubMed
    40. Roland CL, Starker LF, Kang Y, Chatterjee D, Estrella J, Rashid A, Katz MH, Aloia TA, Lee JE, Dasari A, Yao JC, Fleming JB. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery. 2017 03; 161(3):753-759. PMID: 27816207.
      View in: PubMed
    41. Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926. PMID: 27655712.
      View in: PubMed
    42. Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Öberg K. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol. 2016 11 10; 34(32):3906-3913. PMID: 27621394.
      View in: PubMed
    43. Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, Dasari A, Halperin D, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MH. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2017 01; 21(1):155-163. PMID: 27634306.
      View in: PubMed
    44. Yao JC, Voi M, Rouyrre N, Singh S. Everolimus in ileum neuroendocrine tumours - Authors' reply. Lancet. 2016 Jul 16; 388(10041):236-7. PMID: 27479568.
      View in: PubMed
    45. Halperin DM, Dasari A, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas. 2016 07; 45(6):783-5. PMID: 27295529.
      View in: PubMed
    46. Qiu W, Christakis I, Silva A, Bassett RL, Cao L, Meng QH, Gardner Grubbs E, Zhao H, Yao JC, Lee JE, Perrier ND. Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients. Clin Endocrinol (Oxf). 2016 09; 85(3):400-7. PMID: 27256431.
      View in: PubMed
    47. Pearman TP, Beaumont JL, Cella D, Neary MP, Yao J. Health-related quality of life in patients with neuroendocrine tumors: an investigation of treatment type, disease status, and symptom burden. Support Care Cancer. 2016 09; 24(9):3695-703. PMID: 27029477.
      View in: PubMed
    48. Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist. 2016 Mar; 21(3):308-13. PMID: 26911407.
      View in: PubMed
    49. Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016; 9:773-80. PMID: 26929648.
      View in: PubMed
    50. Halperin DM, Yao JC. Clinical Trial Design in Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30(1):209-17. PMID: 26614378.
      View in: PubMed
    51. Halperin DM, Dasari A, Yao JC. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol. 2016 Feb; 12(3):313-21. PMID: 26759064.
      View in: PubMed
    52. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun; 15(2):e1-7. PMID: 26810202.
      View in: PubMed
    53. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 05; 387(10022):968-977. PMID: 26703889.
      View in: PubMed
    54. Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer. 2015 Dec; 22(6):933-40. PMID: 26373569.
      View in: PubMed
    55. Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1656-65. PMID: 26315553.
      View in: PubMed
    56. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol. 2015 Nov 01; 33(31):3583-90. PMID: 26304898.
      View in: PubMed
    57. Prakash L, Lee JE, Yao J, Bhosale P, Balachandran A, Wang H, Fleming JB, Katz MH. Role and Operative Technique of Portal Venous Tumor Thrombectomy in Patients with Pancreatic Neuroendocrine Tumors. J Gastrointest Surg. 2015 Nov; 19(11):2011-8. PMID: 26282850.
      View in: PubMed
    58. Halperin DM, Lee JJ, Dagohoy CG, Yao JC. Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol. 2015 Sep 10; 33(26):2914-9. PMID: 26261263.
      View in: PubMed
    59. Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol. 2015 Jun; 16(6):695-703. PMID: 25956795.
      View in: PubMed
    60. Ng CS, Hobbs BP, Wei W, Anderson EF, Herron DH, Yao JC, Chandler AG. Effect on perfusion values of sampling interval of computed tomographic perfusion acquisitions in neuroendocrine liver metastases and normal liver. J Comput Assist Tomogr. 2015 May-Jun; 39(3):373-82. PMID: 25626401.
      View in: PubMed
    61. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocr Relat Cancer. 2015 Jun; 22(3):431-41. PMID: 25900182.
      View in: PubMed
    62. Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial. Neuroendocrinology. 2015; 102(1-2):18-25. PMID: 25824001.
      View in: PubMed
    63. Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 2015 Mar; 44(2):190-7. PMID: 25426617.
      View in: PubMed
    64. Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015 Mar; 44(2):181-9. PMID: 25479584.
      View in: PubMed
    65. Oyeniyi J, Wu J, Liu D, Yao JC, Green H, Albritton K, Huh W, Hayes-Jordan A. Treatment of carcinomatosis using cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in adolescents and young adults. Am J Surg. 2015 Apr; 209(4):610-5. PMID: 25746912.
      View in: PubMed
    66. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan; 13(1):78-108. PMID: 25583772.
      View in: PubMed
    67. Dasari A, Yao J. Initial treatment of well-differentiated neuroendocrine tumors. Oncology (Williston Park). 2014 Nov; 28(11):945-7. PMID: 25741544.
      View in: PubMed
    68. Halperin DM, Kulke MH, Yao JC. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med. 2015; 66:1-16. PMID: 25341008.
      View in: PubMed
    69. Estrella JS, Ma LT, Milton DR, Yao JC, Wang H, Rashid A, Broaddus RR. Expression of estrogen-induced genes and estrogen receptor ß in pancreatic neuroendocrine tumors: implications for targeted therapy. Pancreas. 2014 Oct; 43(7):996-1002. PMID: 25058880.
      View in: PubMed
    70. Dasari A, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology (Williston Park). 2014 Sep; 28(9):762-3. PMID: 25224473.
      View in: PubMed
    71. Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM. A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. BMC Cancer. 2014 Aug 02; 14:561. PMID: 25086465.
      View in: PubMed
    72. Estrella JS, Broaddus RR, Mathews A, Milton DR, Yao JC, Wang H, Rashid A. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014 Aug; 138(8):1027-36. PMID: 25076292.
      View in: PubMed
    73. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14. PMID: 25012985.
      View in: PubMed
    74. Ng CS, Chandler AG, Yao JC, Herron DH, Anderson EF, Charnsangavej C, Hobbs BP. Effect of pre-enhancement set point on computed tomographic perfusion values in normal liver and metastases to the liver from neuroendocrine tumors. J Comput Assist Tomogr. 2014 Jul-Aug; 38(4):526-34. PMID: 24651739.
      View in: PubMed
    75. Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014 Sep 15; 120(18):2814-23. PMID: 24771552.
      View in: PubMed
    76. Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 01; 120(13):2039-49. PMID: 24676892.
      View in: PubMed
    77. Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2014 Feb; 21(1):22-7. PMID: 24310147.
      View in: PubMed
    78. Ng CS, Hobbs BP, Chandler AG, Anderson EF, Herron DH, Charnsangavej C, Yao J. Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values. Radiology. 2013 Dec; 269(3):758-67. PMID: 23824990.
      View in: PubMed
    79. Ajani JA, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9. PMID: 23975663.
      View in: PubMed
    80. Chau I, Casciano R, Willet J, Wang X, Yao JC. Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. Eur J Cancer Care (Engl). 2013 Nov; 22(6):714-25. PMID: 23895457.
      View in: PubMed
    81. Yao JC, Meric-Bernstam F, Lee JJ, Eckhardt SG. Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin Cancer Res. 2013 Aug 15; 19(16):4305-8. PMID: 23833307.
      View in: PubMed
    82. Boyd AE, DeFord LL, Mares JE, Leary CC, Garris JL, Dagohoy CG, Boving VG, Brook JP, Phan A, Yao JC. Improving the success rate of gluteal intramuscular injections. Pancreas. 2013 Jul; 42(5):878-82. PMID: 23508015.
      View in: PubMed
    83. Landry CS, Lin HY, Phan A, Charnsangavej C, Abdalla EK, Aloia T, Nicolas Vauthey J, Katz MH, Yao JC, Fleming JB. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013 Jul; 37(7):1695-700. PMID: 23657749.
      View in: PubMed
    84. Abrams JS, Mooney MM, Zwiebel JA, Korn EL, Friedman SH, Finnigan SR, Schettino PR, Denicoff AM, Kruhm MG, Montello M, Misra RR, Ansher SS, DiPiazza KJ, Souhan EM, Wickerham DL, Giantonio BJ, O'Donnell RT, Sullivan DM, Soto NI, Fleming GF, Prindiville SA, Petryshyn RA, Hautala JA, Grad O, Zuckerman BL, Meyer RM, Yao JC, Baker LA, Buckner JC, Hortobagyi GN, Doroshow JH. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul 03; 105(13):954-9. PMID: 23776198.
      View in: PubMed
    85. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May; 42(4):557-77. PMID: 23591432.
      View in: PubMed
    86. Yao JC, Lagunes DR, Kulke MH. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist. 2013; 18(5):525-32. PMID: 23615698.
      View in: PubMed
    87. Yao JC, Phan AT, Jehl V, Shah G, Meric-Bernstam F. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013 Mar 01; 73(5):1449-53. PMID: 23436795.
      View in: PubMed
    88. Yao J, Reidy Lagunes D, Kulke MH. In reply. Oncologist. 2013; 18(11):1240-1. PMID: 24218002.
      View in: PubMed
    89. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013 Jan 01; 31(1):17-22. PMID: 23129736.
      View in: PubMed
    90. Hess GP, Chen CC, Liu Z, Yao JC, Phan AT, Hill JW. Clinical burden of illness in patients with neuroendocrine tumors. Pancreas. 2012 Oct; 41(7):1058-62. PMID: 22513292.
      View in: PubMed
    91. Serra S, Zheng L, Hassan M, Phan AT, Woodhouse LJ, Yao JC, Ezzat S, Asa SL. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res. 2012 Nov 15; 72(22):5683-91. PMID: 22986737.
      View in: PubMed
    92. Balachandran A, Tamm EP, Bhosale PR, Katz MH, Fleming JB, Yao JC, Charnsangavej C. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol. 2012 Sep; 199(3):602-8. PMID: 22915400.
      View in: PubMed
    93. Metz DC, Choi J, Strosberg J, Heaney AP, Howden CW, Klimstra D, Yao JC. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2012 Aug; 19(4):306-13. PMID: 22760514.
      View in: PubMed
    94. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):724-64. PMID: 22679117.
      View in: PubMed
    95. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012 Apr; 41(3):461-6. PMID: 22422138.
      View in: PubMed
    96. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89. PMID: 22422409.
      View in: PubMed
    97. Dong M, Phan AT, Yao JC. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res. 2012 Apr 01; 18(7):1830-6. PMID: 22338018.
      View in: PubMed
    98. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Öberg K, Van Cutsem E, Yao JC. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10; 378(9808):2005-2012. PMID: 22119496.
      View in: PubMed
    99. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011 Dec; 96(12):3741-9. PMID: 21994954.
      View in: PubMed
    100. Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, Shah CP, Ross WA, Yao J, Raju GS, Wang X, Lee JH. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig Dis Sci. 2012 Mar; 57(3):791-800. PMID: 21964743.
      View in: PubMed
    101. Yao JC, Phan A. Overcoming antiangiogenic resistance. Clin Cancer Res. 2011 Aug 15; 17(16):5217-9. PMID: 21828238.
      View in: PubMed
    102. Gaur P, Sceusi EL, Samuel S, Xia L, Fan F, Zhou Y, Lu J, Tozzi F, Lopez-Berestein G, Vivas-Mejia P, Rashid A, Fleming JB, Abdalla EK, Curley SA, Vauthey JN, Sood AK, Yao JC, Ellis LM. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011 Nov; 141(5):1728-37. PMID: 21806944.
      View in: PubMed
    103. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011 Jun 14; 4:29. PMID: 21672194.
      View in: PubMed
    104. Salazar R, Reidy-Lagunes D, Yao J. Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs. 2011 May 07; 71(7):841-52. PMID: 21568362.
      View in: PubMed
    105. Dong M, Yao JC. mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr Relat Cancer. 2011 Jun; 18(3):C15-8. PMID: 21427170.
      View in: PubMed
    106. Ng CS, Charnsangavej C, Wei W, Yao JC. Perfusion CT findings in patients with metastatic carcinoid tumors undergoing bevacizumab and interferon therapy. AJR Am J Roentgenol. 2011 Mar; 196(3):569-76. PMID: 21343498.
      View in: PubMed
    107. Capdevila J, Salazar R, Halperín I, Abad A, Yao JC. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev. 2011 Mar; 30 Suppl 1:27-34. PMID: 21311955.
      View in: PubMed
    108. Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart J, Motzer RJ. Research and innovation in the development of everolimus for oncology. Expert Opin Drug Discov. 2011 Mar; 6(3):323-38. PMID: 22647206.
      View in: PubMed
    109. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6):514-23. PMID: 21306238.
      View in: PubMed
    110. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43. PMID: 21263089.
      View in: PubMed
    111. Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2011 Feb; 18(1):171-80. PMID: 21139019.
      View in: PubMed
    112. Yao JC, Catena L, Colao A, Paganelli G. Perspectives in the development of novel treatment approaches. Tumori. 2010 Sep-Oct; 96(5):858-73. PMID: 21302643.
      View in: PubMed
    113. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010 Aug; 39(6):735-52. PMID: 20664472.
      View in: PubMed
    114. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010 Aug; 39(6):753-66. PMID: 20664473.
      View in: PubMed
    115. Gaur P, Leary C, Yao JC. Thymic neuroendocrine tumors: a SEER database analysis of 160 patients. Ann Surg. 2010 Jun; 251(6):1117-21. PMID: 20485130.
      View in: PubMed
    116. Ajani JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63. PMID: 20143431.
      View in: PubMed
    117. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53. PMID: 20108336.
      View in: PubMed
    118. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010 Mar; 34(3):300-13. PMID: 20118772.
      View in: PubMed
    119. Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010 Feb 01; 70(3):1111-9. PMID: 20086170.
      View in: PubMed
    120. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 01; 28(1):69-76. PMID: 19933912.
      View in: PubMed
    121. Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Netw. 2009 Jul; 7(7):712-47. PMID: 19635226.
      View in: PubMed
    122. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009 Mar 01; 15(5):1821-9. PMID: 19223493.
      View in: PubMed
    123. Truong CD, Feng W, Li W, Khoury T, Li Q, Alrawi S, Yu Y, Xie K, Yao J, Tan D. Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res. 2009 Feb 03; 28:14. PMID: 19192297.
      View in: PubMed
    124. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 08; 360(2):195-7. PMID: 19129539.
      View in: PubMed
    125. Phan AT, Yao JC, Evans DB. Treatment options for metastatic neuroendocrine tumors. Surgery. 2008 Dec; 144(6):895-8. PMID: 19040994.
      View in: PubMed
    126. Phan AT, Yao JC. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology (Williston Park). 2008 Dec; 22(14):1617-23; discussion 1623-4, 1629. PMID: 19198220.
      View in: PubMed
    127. Badgwell B, Cormier JN, Xing Y, Yao J, Bose D, Krishnan S, Pisters P, Feig B, Mansfield P. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009 Jan; 16(1):42-50. PMID: 18985270.
      View in: PubMed
    128. Yao JC, Kvols LK. Octreotide LAR in carcinoid: how to dose? Pancreas. 2008 Oct; 37(3):337-8; author reply 338-9. PMID: 18815562.
      View in: PubMed
    129. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10; 26(26):4311-8. PMID: 18779618.
      View in: PubMed
    130. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008 Aug 15; 123(4):867-73. PMID: 18491401.
      View in: PubMed
    131. Al-Refaie WB, Tseng JF, Gay G, Patel-Parekh L, Mansfield PF, Pisters PW, Yao JC, Feig BW. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer. 2008 Aug 01; 113(3):461-9. PMID: 18553367.
      View in: PubMed
    132. Badgwell B, Cormier JN, Krishnan S, Yao J, Staerkel GA, Lupo PJ, Pisters PW, Feig B, Mansfield P. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol. 2008 Oct; 15(10):2684-91. PMID: 18649106.
      View in: PubMed
    133. Wang L, Guan X, Zhang J, Jia Z, Wei D, Li Q, Yao J, Xie K. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol. 2008 Jul; 33(1):161-7. PMID: 18575762.
      View in: PubMed
    134. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18):3063-72. PMID: 18565894.
      View in: PubMed
    135. Truong CD, Li W, Feng W, Cagle P, Khoury T, Alrawi S, Xie K, Yao J, Tan D. Alpha-methylacyl-CoA racemase expression is upregulated in gastric adenocarcinoma: a study of 249 cases. Int J Clin Exp Pathol. 2008 Apr 10; 1(6):518-23. PMID: 18787636.
      View in: PubMed
    136. Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan; 63(2):363-70. PMID: 18398613.
      View in: PubMed
    137. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008 Apr; 17(4):959-65. PMID: 18398037.
      View in: PubMed
    138. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23. PMID: 18323556.
      View in: PubMed
    139. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66. PMID: 18310292.
      View in: PubMed
    140. Kim DH, Nagano Y, Choi IS, White JA, Yao JC, Rashid A. Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer. 2008 Jan; 47(1):84-92. PMID: 17943967.
      View in: PubMed
    141. Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008 Jan; 19(1):145-51. PMID: 18192482.
      View in: PubMed
    142. Feng W, Brown RE, Trung CD, Li W, Wang L, Khoury T, Alrawi S, Yao J, Xia K, Tan D. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. Ann Clin Lab Sci. 2008; 38(3):195-209. PMID: 18715846.
      View in: PubMed
    143. Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, Le X, Wang H, Yao J, Xie K. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer. 2007 Dec 15; 110(12):2682-90. PMID: 17973266.
      View in: PubMed
    144. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, Arnold R, Auernhammer C, Körner M, Rindi G, Wildi S. Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008; 87(1):8-19. PMID: 18097129.
      View in: PubMed
    145. Ramage JK, Goretzki PE, Manfredi R, Komminoth P, Ferone D, Hyrdel R, Kaltsas G, Kelestimur F, Kvols L, Scoazec JY, Garcia MI, Caplin ME. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology. 2008; 87(1):31-9. PMID: 18097130.
      View in: PubMed
    146. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J, Delle Fave GF, O'Toole D. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008; 87(1):47-62. PMID: 18097131.
      View in: PubMed
    147. Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 2007 Nov 15; 110(10):2186-90. PMID: 17896785.
      View in: PubMed
    148. Ahlman H, Nilsson O, McNicol AM, Ruszniewski P, Niederle B, Ricke J, Jensen R, Kos-Kudla B, Oberg K, O'Connor JM, Pavel ME, Vullierme MP. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008; 87(1):40-6. PMID: 17940332.
      View in: PubMed
    149. Plöckinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH, Knigge UP, Kulke MH, Pape UF. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology. 2008; 87(1):20-30. PMID: 17934252.
      View in: PubMed
    150. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans DB. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007 Dec; 14(12):3492-500. PMID: 17896148.
      View in: PubMed
    151. Van Buren G, Rashid A, Yang AD, Abdalla EK, Gray MJ, Liu W, Somcio R, Fan F, Camp ER, Yao JC, Ellis LM. The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res. 2007 Aug 15; 13(16):4704-12. PMID: 17699847.
      View in: PubMed
    152. Yao JC, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. Hematol Oncol Clin North Am. 2007 Jun; 21(3):575-81; x. PMID: 17548041.
      View in: PubMed
    153. Nagano Y, Kim DH, Zhang L, White JA, Yao JC, Hamilton SR, Rashid A. Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer. 2007 Jun; 14(2):483-92. PMID: 17639061.
      View in: PubMed
    154. Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, Li Q, Yao J, Xie K. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 2007 May 15; 67(10):4878-85. PMID: 17510417.
      View in: PubMed
    155. Choi IS, Estecio MR, Nagano Y, Kim DH, White JA, Yao JC, Issa JP, Rashid A. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol. 2007 Jul; 20(7):802-10. PMID: 17483816.
      View in: PubMed
    156. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer. 2007 Apr 15; 109(8):1478-86. PMID: 17340592.
      View in: PubMed
    157. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007 Mar; 21(1):163-72. PMID: 17382271.
      View in: PubMed
    158. Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H, Pauwels S, Kwekkeboom DJ, Rindi G. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006; 84(3):158-64. PMID: 17312375.
      View in: PubMed
    159. Nilsson O, Van Cutsem E, Delle Fave G, Yao JC, Pavel ME, McNicol AM, Sevilla Garcia MI, Knapp WH, Kelestimur F, Sauvanet A, Pauwels S, Kwekkeboom DJ, Caplin M. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology. 2006; 84(3):212-5. PMID: 17312381.
      View in: PubMed
    160. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O'Toole D, Ferone D. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006; 84(3):183-8. PMID: 17312378.
      View in: PubMed
    161. Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmuller T, Oberg K, Scoazec JY. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006; 84(3):196-211. PMID: 17312380.
      View in: PubMed
    162. O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme MP, Caplin M, Jensen R, Eriksson B. Rare functioning pancreatic endocrine tumors. Neuroendocrinology. 2006; 84(3):189-95. PMID: 17312379.
      View in: PubMed
    163. Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Bechstein WO, Christ E, Taal BG, Knigge U, Ahlman H, Kwekkeboom DJ, O'Toole D. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology. 2006; 84(3):165-72. PMID: 17312376.
      View in: PubMed
    164. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O'Connor JM, Pauwels S, Kloppel G. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006; 84(3):173-82. PMID: 17312377.
      View in: PubMed
    165. Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J, Tabernero J. New drug development in digestive neuroendocrine tumors. Ann Oncol. 2007 Aug; 18(8):1307-13. PMID: 17301070.
      View in: PubMed
    166. Wang LW, Li Q, Hua ZL, Zhou F, Keping X, Daoyan W, Yao J, Ajani J. [Expression of transcription factor Sp1 in human gastric cancer tissue and its correlation with prognosis]. Zhonghua Zhong Liu Za Zhi. 2007 Feb; 29(2):107-11. PMID: 17645844.
      View in: PubMed
    167. Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, Strumberg D, Yanagihara R, Yao JC, Phan AT, Ajani JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer. 2007 Jan 01; 109(1):33-40. PMID: 17133415.
      View in: PubMed
    168. Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 01; 13(1):234-40. PMID: 17200360.
      View in: PubMed
    169. Zhang J, Jiang Y, Jia Z, Li Q, Gong W, Wang L, Wei D, Yao J, Fang S, Xie K. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006; 23(7-8):401-10. PMID: 17187227.
      View in: PubMed
    170. Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 2006 Dec 01; 107(11):2576-80. PMID: 17075877.
      View in: PubMed
    171. Kanai M, Wei D, Li Q, Jia Z, Ajani J, Le X, Yao J, Xie K. Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. Clin Cancer Res. 2006 Nov 01; 12(21):6395-402. PMID: 17085651.
      View in: PubMed
    172. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006 Oct; 449(4):395-401. PMID: 16967267.
      View in: PubMed
    173. Madoff DC, Gupta S, Ahrar K, Murthy R, Yao JC. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006 Aug; 17(8):1235-49; quiz 1250. PMID: 16923972.
      View in: PubMed
    174. Ajani JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006 Jul; 24(4):353-7. PMID: 16683077.
      View in: PubMed
    175. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB, Perrier ND. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg. 2006 May; 30(5):643-53. PMID: 16680581.
      View in: PubMed
    176. Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006 Feb 01; 24(4):663-7. PMID: 16446338.
      View in: PubMed
    177. Liu L, Broaddus RR, Yao JC, Xie S, White JA, Wu TT, Hamilton SR, Rashid A. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol. 2005 Dec; 18(12):1632-40. PMID: 16258509.
      View in: PubMed
    178. Mullen JT, Wang H, Yao JC, Lee JH, Perrier ND, Pisters PW, Lee JE, Evans DB. Carcinoid tumors of the duodenum. Surgery. 2005 Dec; 138(6):971-7; discussion 977-8. PMID: 16360380.
      View in: PubMed
    179. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005 Oct 15; 104(8):1590-602. PMID: 16134179.
      View in: PubMed
    180. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 01; 23(28):6957-65. PMID: 16145066.
      View in: PubMed
    181. Gong W, Jiang Y, Wang L, Wei D, Yao J, Huang S, Fang S, Xie K. Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5778-83. PMID: 16115916.
      View in: PubMed
    182. Wang GG, Yao JC, Worah S, White JA, Luna R, Wu TT, Hamilton SR, Rashid A. Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. Mod Pathol. 2005 Aug; 18(8):1079-87. PMID: 15920555.
      View in: PubMed
    183. Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang L, Le X, Yao J, Wu TT, Huang S, Xie K. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 2005 Jun 01; 65(11):4809-16. PMID: 15930301.
      View in: PubMed
    184. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol. 2005 May 01; 23(13):3094-103. PMID: 15860869.
      View in: PubMed
    185. Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC, Wu TT, Huang S, Xie K. Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 2005 Apr 01; 65(7):2746-54. PMID: 15805274.
      View in: PubMed
    186. Zhang Z, Liao Z, Jin J, Ajani J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64. PMID: 15708243.
      View in: PubMed
    187. Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB. Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol. 2005 Mar 01; 89(3):170-85. PMID: 15719379.
      View in: PubMed
    188. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005 Feb 20; 23(6):1237-44. PMID: 15718321.
      View in: PubMed
    189. Gong W, Wang L, Yao JC, Ajani JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res. 2005 Feb 15; 11(4):1386-93. PMID: 15746037.
      View in: PubMed
    190. An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, Ajani JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):656-63. PMID: 15701853.
      View in: PubMed
    191. Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S, Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. Gastric Cancer. 2005; 8(1):18-28. PMID: 15747170.
      View in: PubMed
    192. Wang L, Guan X, Gong W, Yao J, Peng Z, Wei D, Wu TT, Huang S, Xie K. Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis. 2005; 22(3):205-13. PMID: 16158248.
      View in: PubMed
    193. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004 Dec 01; 22(23):4762-71. PMID: 15570077.
      View in: PubMed
    194. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93. PMID: 15590179.
      View in: PubMed
    195. Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36. PMID: 15380576.
      View in: PubMed
    196. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam JB, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z, Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao J, Roth JA. Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol. 2004 Jul; 99(7):1258-66. PMID: 15233663.
      View in: PubMed
    197. Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J, Xie K. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4109-17. PMID: 15217947.
      View in: PubMed
    198. Kibbe MR, Ujiki M, Goodwin AL, Eskandari M, Yao J, Matsumura J. Iliac vein compression in an asymptomatic patient population. J Vasc Surg. 2004 May; 39(5):937-43. PMID: 15111841.
      View in: PubMed
    199. Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, Ajani JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004; 17(1):38-43. PMID: 15209739.
      View in: PubMed
    200. Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, Xie K. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64. PMID: 16035620.
      View in: PubMed
    201. Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003 Dec 15; 9(17):6371-80. PMID: 14695137.
      View in: PubMed
    202. Yao JC, Vauthey JN. Primary and metastatic hepatic carcinoid: is there an algorithm? Ann Surg Oncol. 2003 Dec; 10(10):1133-5. PMID: 14654466.
      View in: PubMed
    203. Ajani JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):20-2. PMID: 14569843.
      View in: PubMed
    204. Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol. 2003 Aug; 4(8):498-505. PMID: 12901965.
      View in: PubMed
    205. Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J. 2003 Jul-Aug; 9(4):261-7. PMID: 12967136.
      View in: PubMed
    206. Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol. 2003 Apr; 26(2):165-70. PMID: 12714889.
      View in: PubMed
    207. Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003; 21(4):223-7. PMID: 14648779.
      View in: PubMed
    208. Schnirer II, Yao JC, Ajani JA. Carcinoid--a comprehensive review. Acta Oncol. 2003; 42(7):672-92. PMID: 14690153.
      View in: PubMed
    209. Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep. 2002 May; 4(3):222-8. PMID: 11937012.
      View in: PubMed
    210. Yao JC, Ajani JA. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12. PMID: 12401660.
      View in: PubMed
    211. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, Ajani JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12. PMID: 12491078.
      View in: PubMed
    212. Schnirer II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, Ajani JA. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001 Feb; 24(1):91-5. PMID: 11232959.
      View in: PubMed
    213. Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol. 2000 Nov; 16(6):516-21. PMID: 17031130.
      View in: PubMed
    214. Ajani JA, Yao JC. Preoperative therapy for local-regional gastric cancer: rationale and review of trials. Gan To Kagaku Ryoho. 2000 May; 27 Suppl 2:392-4. PMID: 10895184.
      View in: PubMed
    215. Yao JC, Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma: closing out the century. Oncology (Williston Park). 1999 Nov; 13(11):1485-94; discussion 1497-502 passim. PMID: 10581599.
      View in: PubMed
    216. Yao JC, Thomakos N, McLaughlin P, Buchholz TA, Kudelka AP. Tamoxifen-induced thrombocytopenia. Am J Clin Oncol. 1999 Oct; 22(5):529-32. PMID: 10521073.
      View in: PubMed
    217. Optimising therapeutic options for patients with advanced pancreatic neuroendocrine tumours. European Oncology and Haematology. 8:217-223.
    218. Role of mTOR inhibitor in the management of NETs. Tumori. 96:858-861.
    219. Personalized medicine and targeted therapy of neuroendocrine neoplasms. 790-796.
    220. Role and Operative Technique of Portal Venous Tumor Thrombectomy in Patients with Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery.
    221. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncology. 12:313-321.
    222. Pancreatic neuroendocrine tumors. 193-209.
    223. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors. Pancreas.
    224. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery (United States).
    225. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 7:69916-69926.
    226. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. Journal of Gastrointestinal Surgery. 1-9.
    227. Initial treatment of well-differentiated neuroendocrine tumors. ONCOLOGY (United States). 28.
    228. In reply. Journal of Clinical Oncology. 26:6013-6015.
    229. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors. Clinical Pharmacology and Therapeutics.
    230. Health-related quality of life in patients with neuroendocrine tumors. Supportive Care in Cancer. 1-9.
    231. Meta-analysis of stomatitis in clinical studies of everolimus. Annals of Oncology. 27:519-525.
    232. High-Grade Neuroendocrine Colorectal Carcinomas. Clinical Colorectal Cancer.
    233. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas. 45:783-785.
    234. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors. Journal of Clinical Oncology. 34:3906-3913.
    235. Phase i study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer. 22:431-441.
    236. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. OncoTargets and Therapy. 9:773-780.
    237. Neuroendocrine cancers. 301-324.
    238. Re. Oncologist. 18:1240-1241.
    239. Perfusion Computed Tomography as Functional Biomarker in Randomized Run-In Study of Bevacizumab and Everolimus in Well-Differentiated Neuroendocrine Tumors. Pancreas.
    240. Gastrointestinal neuroendocrine tumors. ONCOLOGY (United States). 28.
    241. Electronic Clinical Challenges and Images in GI. Gastroenterology. 133.
    242. Preface. Hematology/Oncology Clinics of North America. 21.
    243. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors. Endocrine-Related Cancer. 22:933-940.
    244. American Society of Clinical Oncology, 45th Annual Meeting - Effect of octreotide (Sandostatin LAR) for neuroendocrine midgut tumors. P and T. 34:379.
    245. Pancreatic neuroendocrine tumors.
    246. Dr. Yao and colleagues reply. New England Journal of Medicine. 364:1874-1875.
    247. Octreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumors. Oncologist. 21:308-313.
    YAO's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description